Janney Capital Management LLC lowered its position in shares of Sanofi SA (NYSE:SNY) by 1.6% during the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 508,488 shares of the company’s stock after selling 8,106 shares during the period. Sanofi comprises about 1.1% of Janney Capital Management LLC’s holdings, making the stock its 24th largest position. Janney Capital Management LLC’s holdings in Sanofi were worth $25,317,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also recently bought and sold shares of the company. Fisher Asset Management LLC increased its position in Sanofi by 3.3% in the 3rd quarter. Fisher Asset Management LLC now owns 14,082,257 shares of the company’s stock valued at $701,156,000 after acquiring an additional 443,799 shares during the period. Assetmark Inc. increased its position in Sanofi by 34.4% in the 3rd quarter. Assetmark Inc. now owns 158,305 shares of the company’s stock valued at $7,882,000 after acquiring an additional 40,484 shares during the period. AMG National Trust Bank increased its position in Sanofi by 5.3% in the 2nd quarter. AMG National Trust Bank now owns 51,423 shares of the company’s stock valued at $2,464,000 after acquiring an additional 2,594 shares during the period. Alethea Capital Management LLC acquired a new position in Sanofi in the 3rd quarter valued at about $794,000. Finally, Parallel Advisors LLC increased its position in Sanofi by 42.5% in the 2nd quarter. Parallel Advisors LLC now owns 2,934 shares of the company’s stock valued at $139,000 after acquiring an additional 875 shares during the period. Institutional investors and hedge funds own 9.09% of the company’s stock.
Several brokerages recently issued reports on SNY. Argus restated a “buy” rating and issued a $55.00 price target on shares of Sanofi in a research report on Friday, September 1st. Bank of America cut Sanofi from a “buy” rating to a “neutral” rating in a research report on Wednesday, December 6th. Barclays upgraded Sanofi from an “underweight” rating to an “equal weight” rating in a research report on Wednesday, November 15th. Zacks Investment Research cut Sanofi from a “hold” rating to a “strong sell” rating in a research report on Friday, October 6th. Finally, J P Morgan Chase & Co restated a “neutral” rating on shares of Sanofi in a research report on Friday, September 15th. Two investment analysts have rated the stock with a sell rating, nine have given a hold rating and three have issued a buy rating to the company. The stock presently has an average rating of “Hold” and an average price target of $53.50.
Shares of Sanofi SA (NYSE:SNY) traded down $0.05 on Monday, reaching $43.24. The company’s stock had a trading volume of 923,200 shares, compared to its average volume of 1,498,906. Sanofi SA has a 12 month low of $38.45 and a 12 month high of $50.65. The stock has a market cap of $108,810.00, a price-to-earnings ratio of 13.64, a PEG ratio of 2.57 and a beta of 0.86. The company has a debt-to-equity ratio of 0.26, a current ratio of 1.59 and a quick ratio of 1.16.
ILLEGAL ACTIVITY NOTICE: This piece of content was reported by Transcript Daily and is the sole property of of Transcript Daily. If you are viewing this piece of content on another site, it was copied illegally and reposted in violation of United States and international copyright law. The correct version of this piece of content can be read at https://transcriptdaily.com/2017/12/11/sanofi-sa-sny-shares-sold-by-janney-capital-management-llc.html.
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
Receive News & Ratings for Sanofi SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi SA and related companies with MarketBeat.com's FREE daily email newsletter.